ThinkstockThe hunt by Big Pharma stocks for smaller drug companies and biotech stocks continues. A report citing “sources” from Dow Jones News has signaled that Bristol-Myers Squibb (NYSE: BMY) has considered large…
Thinkstock24/7 Wall St. has always wondered about the confusing universe of biotech exchange-traded funds (ETFs). Biotech stocks can rise or fall regardless of the market direction, and the sector performed very well…
The Fidelity Contrafund has released its 2012 annual report for its shareholders. While the date is December 31, 2012, and the asset size is listed as more than $84 billion as of…
Jon OggThese are some of this Wednesday’s top analyst upgrades, downgrades and initiations seen from Wall St. research calls. Allscripts Healthcare Solutions Inc. (NASDAQ: MDRX) raised to Outperform with $15 price target at…
U.S. equity markets opened higher this morning boosted by higher-than-expected trade balances in China (more coverage here) and in the U.S. (more coverage here). In Europe the big news came later in…
ThinkstockInvesting in biotech or biopharmaceutical stocks can prove to be a very daunting task. Many of the stocks have limited pipelines or their very survival depends on a single binary event that…
Jon OggThese are some of this Friday’s top analyst upgrades, downgrades and initiations seen from Wall St. research calls. Alcatel-Lucent S.A. (NYSE: ALU) raised to Overweight at Morgan Stanley and reiterated Hold…
ThinkstockBiogen Idec Inc. (NASDAQ: BIIB) may be a half decade or so late on this move, but as the saying goes “better late than never.” The biotech and drug company is the leader in…
Jon OggThese are some of the top analyst upgrades, downgrades and initiations seen from Wall St. research calls this Tuesday. Abercrombie & Fitch Co. (NYSE: ANF) raised to Outperform at BMO. American…
U.S. equity markets opened mixed this morning on relatively little new data. In Europe, Italian consumer confidence rose more than expected and Germany auctioned 12-month bills at a positive yield for the…
ThinkstockBiogen Idec Inc. (NASDAQ: BIIB) reported fourth-quarter and full-year 2012 results before markets opened this morning. For the quarter, the biotech firm posted adjusted diluted earnings per share (EPS) of $1.40 on…
Paul Ausick U.S. equity markets opened higher this morning before dipping following the report on new home sales in the U.S. Stocks regained positive momentum during most of the remaining session. In Europe, Germany’s…
Jon OggThese are some of the top analyst upgrades, downgrades and initiations seen so far this Tuesday. There is a larger concentration around biotech and emerging pharma this morning, but that is…
ThinkstockBig biotech had a stellar 2012. In 2013, though, the large biotech companies may be dwarfed in performance by the smaller players in the $1 billion to $5 billion range. If you…
ThinkstockBiogen Idec Inc. (NASDAQ: BIIB) is living up to why we just said it is now an overvalued biotech stock for 2013. Biogen Idec and the other biotech giants had risen perhaps too much in…
Jon C. Ogg 